Jiang Chen1, Hongyu Li1, Wenda Xu1, Xiaozhong Guo2. 1. Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110840, Liaoning Province, China. 2. Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110840, Liaoning Province, China. guoxiaozhong1962@126.com.
Abstract
BACKGROUND: Pancreatic cancer (PC) is a devastating disease that has a poor prognosis and a total 5-year survival rate of around 5%. The poor prognosis of PC is due in part to a lack of suitable biomarkers that can allow early diagnosis. The lysophospholipase autotaxin (ATX) and its product lysophosphatidic acid (LPA) play an essential role in disease progression in PC patients and are associated with increased morbidity in several types of cancer. In this study, we evaluated both the potential role of serum LPA and ATX as diagnostic markers in PC and their prognostic value for PC either alone or in combination with CA19-9. METHODS: ATX, LPA and CA19-9 levels were evaluated using ELISA of serum obtained from PC patients (n = 114) healthy volunteers (HVs: n = 120) and patients with benign pancreatic diseases (BPDs: n = 94). RESULTS: Serum levels of ATX, LPA and CA19-9 in PC patients were substantially higher than that for BPD patients or HVs (p < 0.001). The sensitivity of LPA in early phase PC was 91.74% and the specificity of ATX was 80%. The levels of ATX, LPA and CA19-9 were all substantially higher for early stage PC patients compared to levels in serum from BPD patients and HVs. The diagnostic efficacy of CA19-9 for PC was significantly enhanced by the addition of ATX and LPA (p = 0.0012). CONCLUSION: Measurement of LPA and ATX levels together with CA19-9 levels can be used for early detection of PC and diagnosis of PC in general.
BACKGROUND: Pancreatic cancer (PC) is a devastating disease that has a poor prognosis and a total 5-year survival rate of around 5%. The poor prognosis of PC is due in part to a lack of suitable biomarkers that can allow early diagnosis. The lysophospholipase autotaxin (ATX) and its product lysophosphatidic acid (LPA) play an essential role in disease progression in PC patients and are associated with increased morbidity in several types of cancer. In this study, we evaluated both the potential role of serum LPA and ATX as diagnostic markers in PC and their prognostic value for PC either alone or in combination with CA19-9. METHODS: ATX, LPA and CA19-9 levels were evaluated using ELISA of serum obtained from PC patients (n = 114) healthy volunteers (HVs: n = 120) and patients with benign pancreatic diseases (BPDs: n = 94). RESULTS: Serum levels of ATX, LPA and CA19-9 in PC patients were substantially higher than that for BPD patients or HVs (p < 0.001). The sensitivity of LPA in early phase PC was 91.74% and the specificity of ATX was 80%. The levels of ATX, LPA and CA19-9 were all substantially higher for early stage PC patients compared to levels in serum from BPD patients and HVs. The diagnostic efficacy of CA19-9 for PC was significantly enhanced by the addition of ATX and LPA (p = 0.0012). CONCLUSION: Measurement of LPA and ATX levels together with CA19-9 levels can be used for early detection of PC and diagnosis of PC in general.
Authors: Charlotte E A Stuart; Ruma G Singh; Gisselle C Alarcon Ramos; Sunitha Priya; Juyeon Ko; Steve V DeSouza; Jaelim Cho; Maxim S Petrov Journal: Pancreatology Date: 2019-11-01 Impact factor: 3.996
Authors: Christopher L Wolfgang; Joseph M Herman; Daniel A Laheru; Alison P Klein; Michael A Erdek; Elliot K Fishman; Ralph H Hruban Journal: CA Cancer J Clin Date: 2013-07-15 Impact factor: 508.702
Authors: K Bandoh; J Aoki; H Hosono; S Kobayashi; T Kobayashi; K Murakami-Murofushi; M Tsujimoto; H Arai; K Inoue Journal: J Biol Chem Date: 1999-09-24 Impact factor: 5.157
Authors: Chang-Suk Chae; Tito A Sandoval; Sung-Min Hwang; Eun Sil Park; Paolo Giovanelli; Deepika Awasthi; Camilla Salvagno; Alexander Emmanuelli; Chen Tan; Vidyanath Chaudhary; Julia Casado; Andrew V Kossenkov; Minkyung Song; Franck J Barrat; Kevin Holcomb; E Alfonso Romero-Sandoval; Dmitriy Zamarin; David Pépin; Alan D D'Andrea; Anniina Färkkilä; Juan R Cubillos-Ruiz Journal: Cancer Discov Date: 2022-08-05 Impact factor: 38.272
Authors: María Flores-López; Nuria García-Marchena; Pedro Araos; Nerea Requena-Ocaña; Oscar Porras-Perales; Sandra Torres-Galván; Juan Suarez; Nieves Pizarro; Rafael de la Torre; Gabriel Rubio; Juan Jesús Ruiz-Ruiz; Fernando Rodríguez de Fonseca; Antonia Serrano; Francisco Javier Pavón-Morón Journal: Brain Sci Date: 2022-04-30